CBCharles B. Breckenridge

Charles B. Breckenridge

*This is an algorithmically generated author record based on publicly available information.

Charles B. Breckenridge has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Chad D. Foradori

    Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL

    2 shared publications
  • Robert J. Handa

    Department of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, Arizona

    2 shared publications
  • Alicia M Quihuis

    Department of Basic Medical Sciences, College of Medicine–Phoenix, University of Arizona, Phoenix, Arizona

    1 shared publication
  • Anthony F. Lacagnina

    Department of Basic Medical Sciences, College of Medicine–Phoenix, University of Arizona, Phoenix, Arizona

    1 shared publication
  • Arthur D Zimmerman

    Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama

    1 shared publication
  • Arthur D. Zimmerman

    Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States

    1 shared publication

Latest Publications

  • Open Access

    Characterization of Activation of the Hypothalamic-Pituitary-Adrenal Axis by the Herbicide Atrazine in the Female Rat

    by Chad D Foradori, Jessica E Healy, Arthur D Zimmerman, Robert J Kemppainen, Melaney A Jones, Casey C Read, B Douglas White, Kun Don Yi, Laura R Hinds, Anthony F Lacagnina, et al.

    Atrazine (ATR) is a commonly used pre-emergence and early postemergence herbicide. Rats gavaged with ATR and its chlorometabolites desethylatrazine (DEA) and deisopropylatrazine (DIA) respond with a rapid and dose-dependent rise in plasma corticosterone, whereas the major chlorometabolite, diaminochlorotriazine (DACT), has little or no effect on corticosterone levels. In this study, we investigated the possible sites of ATR activation of the hypothalamic-pituitary-adrenal (HPA) axis. ATR treatment had no effect on adrenal weights but altered adrenal morphology. Hypophysectomized rats or rats under dexamethasone suppression did not respond to ATR treatment, suggesting that ATR does not directly stimulate the adrenal gland to induce corticosterone synthesis. Immortalized mouse corticotrophs (AtT-20) and primary rat pituitary cultures were treated with ATR, DEA, DIA, or DACT. None of the compounds induced an increase in ACTH secretion or potentiated ACTH release in conjunction with CRH on ACTH release. In female rats gavaged with ATR, pretreatment with the CRH receptor antagonist astressin completely blocked the ATR-induced rise in corticosterone concentrations, implicating CRH release in ATR-induced HPA activation. Intracerebroventricular infusion of ATR, DEA, and DIA but not DACT at concentrations equivalent to peak plasma concentrations after gavage dosing resulted in an elevation of plasma corticosterone concentrations. However, ATR did not induce c-Fos immunoreactivity in the paraventricular nucleus of the hypothalamus. These results indicate that ATR activates the HPA axis centrally and requires CRH receptor activation, but it does not stimulate cellular pathways associated with CRH neuronal excitation.


  • Open Access

    Changes in Sensitivity to the Effects of Atrazine on the Luteinizing Hormone Surge in Female Sprague‐Dawley Rats after Repeated Daily Doses: Correlation with Liver Enzyme Expression

    by Charles B. Breckenridge, Chad D. Foradori, Pragati Sawhney Coder, James W. Simpkins, Robert L. Sielken, Robert J. Handa

    Background: Atrazine suppression of the LH surge slowly develops over time and peaks after 4 days; sensitivity to atrazine decreases after 8 or 14 days of dosing. Adaptation of the LH response was correlated with increased phase I and phase II liver enzyme activity/expression.Methods: The effect of atrazine on the LH surge was evaluated in female Sprague‐Dawley rats administered 100 mg/kg/day atrazine by gavage for 1, 2, 3, or 4 consecutive days or 6.5, 50, or 100 mg/kg/day atrazine for 4, 8, or 14 days.Results: No statistically significant effects of atrazine were seen on peak plasma LH or LH area under the curve (AUC) after one, two, or three doses of 100 mg/kg/day. Four daily doses of 50 or 100 mg/kg atrazine significantly reduced peak LH and LH AUCs, whereas 6.5 mg/kg/day had no effect. After 8 or 14 days of treatment, statistically significantly reduced peak LH and LH AUC were observed in the 100 mg/kg/day dose group, but not in the 6.5 or 50 mg/kg/day dose groups, although significantly reduced LH was observed in one sample 9 hr after lights‐on in the 50 mg/kg/day dose group on day 14. The number of days of treatment required to achieve a significant suppression of the LH surge is consistent with the repeat‐dose pharmacokinetics of the chlorotriazines.Conclusion: The apparent adaptation to the effect of atrazine on the LH surge after 8 or 14 days may be related to the induction of phase I or, more likely, phase II metabolism observed in this study after 8 days, or to a decreased sensitivity of the hypothalamic‐pituitary‐adrenal axis or an homeostatic adaption of the effect of atrazine on the LH surge mechanism. Birth Defects Research 110:246–258, 2018. © 2017 The Authors. Birth Defects Research Published by Wiley Periodicals, Inc.


  • Open Access

    Lack of immunotoxic effects of repeated exposure to atrazine associated with the adaptation of adrenal gland activation

    by Chad D. Foradori, Arthur D. Zimmerman, Pragati S. Coder, Vanessa L. Peachee, Robert J. Handa, Ian Kimber, Stephen B. Pruett, Charles B. Breckenridge